Literature DB >> 2509413

Emergence of resistance to carbapenem antibiotics in Pseudomonas aeruginosa.

B S Margaret1, G L Drusano, H C Standiford.   

Abstract

Meropenem is a new carbapenem antibiotic with activity similar to that of imipenem. Development of resistance to imipenem by Pseudomonas aeruginosa has occurred in therapy and is associated with loss of a 45,000-48,000 molecular weight outer membrane protein (OMP) and decreased imipenem penetration. Seven pairs of isolates of P. aeruginosa obtained before treatment and after emergence of resistance were examined for changes in MIC of both imipenem and meropenem, and for changes in OMP profile. Resistant mutants were obtained also from the pre-therapy strains on Mueller-Hinton agar containing increasing amounts of either drug, and maintained under antibiotic pressure. OMP preparations of all pre- and post-therapy strains and laboratory mutants were separated by polyacrylamide gel electrophoresis. Loss of a 45,000-48,000 molecular weight protein occurred in variants selected under carbapenem pressure and in all post-therapy isolates. Meropenem remained four-fold more active than imipenem against the resistant strains and mutants.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2509413     DOI: 10.1093/jac/24.suppl_a.161

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  9 in total

1.  Imipenem and meropenem: Comparison of in vitro activity, pharmacokinetics, clinical trials and adverse effects.

Authors:  G G Zhanel; A E Simor; L Vercaigne; L Mandell
Journal:  Can J Infect Dis       Date:  1998-07

Review 2.  Meropenem clinical pharmacokinetics.

Authors:  J W Mouton; J N van den Anker
Journal:  Clin Pharmacokinet       Date:  1995-04       Impact factor: 6.447

3.  Relationship between outer membrane protein profiles and resistance to ceftazidime, imipenem, and ciprofloxacin in Pseudomonas aeruginosa isolates from bacteremic patients.

Authors:  C Gimeno; D Navarro; F Savall; E Millás; M A Farga; J Garau; R Cisterna; J García-de-Lomas
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1996-01       Impact factor: 3.267

4.  Inhibition of bacterial motility with human antiflagellar monoclonal antibodies attenuates Pseudomonas aeruginosa-induced pneumonia in the immunocompetent rat.

Authors:  W J Landsperger; K D Kelly-Wintenberg; T C Montie; L S Knight; M B Hansen; C C Huntenburg; M J Schneidkraut
Journal:  Infect Immun       Date:  1994-11       Impact factor: 3.441

Review 5.  Antibacterial-resistant Pseudomonas aeruginosa: clinical impact and complex regulation of chromosomally encoded resistance mechanisms.

Authors:  Philip D Lister; Daniel J Wolter; Nancy D Hanson
Journal:  Clin Microbiol Rev       Date:  2009-10       Impact factor: 26.132

Review 6.  Meropenem. A review of its antibacterial activity, pharmacokinetic properties and clinical efficacy.

Authors:  L R Wiseman; A J Wagstaff; R N Brogden; H M Bryson
Journal:  Drugs       Date:  1995-07       Impact factor: 9.546

7.  Activity of meropenem against imipenem-resistant bacteria and selection in vitro of carbapenem-resistant Enterobacteriaceae.

Authors:  L J Piddock; H L Turner
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1992-12       Impact factor: 3.267

8.  In vitro activity and killing effect of DX-8739, a new carbapenem, compared with those of meropenem and imipenem against multiresistant Pseudomonas aeruginosa.

Authors:  E J Giamarellos-Bourboulis; P Grecka; H Giamarellou
Journal:  Antimicrob Agents Chemother       Date:  1995-03       Impact factor: 5.191

Review 9.  Molecular epidemiology of carbapenem-resistant Pseudomonas aeruginosa in an endemic area: comparison with global data.

Authors:  Theodoros Karampatakis; Charalampos Antachopoulos; Athanassios Tsakris; Emmanuel Roilides
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2018-04-11       Impact factor: 3.267

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.